Characterization of immunogenic properties of haptenated liposomal model membranes in mice. V. Effect of membrane composition on humoral and cellular immunogenicity.
This paper describes the effect of altering liposomal membrane composition on humoral and cellular immunogenicity of haptenated liposomes in mice. Antibody formation was determined by enumeration of direct, plaque-forming cells in the spleen and delayed-type hypersensitivity (DH) was measured with a footpad swelling test. Humoral immunogenicity of haptenated liposomes was strongly influenced by membrane phospholipid, cholesterol and charged amphiphile composition. Haptenated liposomes prepared from phospholipids with a low (dioleoyl- and dilauroyl-phosphatidylcholine) or high (distearoyl phosphatidylcholine) phase-transition temperature were less immunogenic than those prepared from phospholipids with an intermediate phase-transition temperature (dipalmitoyl phosphatidylcholine and sphingomyelin). In general, increasing the amount of liposomal membrane cholesterol induced a higher humoral response. These results are discussed in relation to liposomal membrane fluidity. Induction of an optimal DH with haptenated liposomes did not occur in the absence of the adjuvant dimethyl dioctadecyl ammonium bromide (DDA). When DDA was used, alterations in membrane composition did not influence cellular immunogenicity. From these results it was concluded that 'intermediate' liposomal membrane fluidity is the most important requirement for induction of optimal antibody formation with haptenated liposomes and that a certain physicochemical configuration of the antigen, provided by the adjuvant DDA, is a prerequisite for induction of DH.
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000917:Antibody Formation; D002784:Cholesterol / Q000276:immunology; D005260:Female; D006241:Haptens / Q000276:immunology*; D006462:Hemolytic Plaque Technique; D007111:Immunity, Cellular; D008050:Lipid A / Q000494:pharmacology; D008081:Liposomes / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010743:Phospholipids / Q000276:immunology; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology; D013501:Surface-Active Agents / Q000276:immunology
D000276:Adjuvants, Immunologic; D006241:Haptens; D008050:Lipid A; D008081:Liposomes; D010743:Phospholipids; D000644:Quaternary Ammonium Compounds; D013501:Surface-Active Agents; C015831:dimethyldioctadecylammonium; D002784:Cholesterol